Human immunodeficiency virus decoy |
| OF THE INVENTION The present invention has wide application to immunologic procedures and methods ... |
|
Capsid forming and cystein modified chimaeric MS2-coat protein |
| We claim: 1. A modified coat protein capable of forming a capsid which comprises the coat protein ... |
|
Strategically modified hepatitis B core proteins and their derivatives |
| The present invention relates to a strategically modified hepatitis B core (HBc) protein that is ... |
|
Chimeric biotin-binding papillomavirus protein |
| OF THE INVENTION The first domain of the chimeric protein includes at least a portion of a ... |
|
MYPPPY variants of CTL A4 and uses thereof |
| OF THE INVENTION Definition As used in this application, the following words or phrases have the ... |
|
CTLA4 receptor and uses thereof |
| OF THE INVENTION DEFINITION As used in this application, the following words or phrases have the ... |
|
CTLA4/CD28Ig hybrid fusion proteins and uses thereof |
| OF THE INVENTION DEFINITION As used in this application, the following words or phrases have the ... |
|
Method of regulating cellular processes mediated by B7 and CD28 |
| Accordingly, the present invention identifies the B7 antigen as a ligand recognized by the CD28 ... |
|
|
Protein tyrosine kinase substrate LAT and its use in the indentification of (ant)agonists of the kinase
| Details |
Inventors: Samelson, Lawrence E.; Zhang, Weiguo;
Assignee: The United States of America as represented by the Department of Health and Human Services (Washington, DC) N/A (
Primary Examiner: Helms; Larry R.
Assistant Examiner: Yu; Misook
Attorney, Agent or Firm: Rucker, Esq.; Susan S. Corless; Peter F. Edwards, Angell, Palmer & Dodge LLP
The invention generally relates to compositions and methods for identifying and testing tyrosine kinase signaling pathway agonists and antagonists, and more particularly, methods and compositions for screening compounds and identifying compounds that will modulate the interaction of protein tyrosine kinase substrates with their intracellular ligands, as well as between their intracellular ligands and other members of the signaling pathway. |
|
DETAILED DESCRIPTION OF SPECIFIC EMBODIMENTS Generally, the nomenclature used hereafter and the laboratory procedures in cell culture, molecular genetics, and nucleic acid chemistry and hybridization described below are those well known and commonly employed in the art. Standard techniques are used for recombinant nucleic acid methods, polynucleotide synthesis, and microbial culture and transformation (e. g. , electroporation, lipofection). Generally enzymatic reactions and purification steps are performed according to the manufacturer's specifications. The techniques and procedures are generally performed according to conventional methods in the art and various general references (see, generally, Sambrook et al. Molecular Cloning: A Laboratory Manual, 2d ed. (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N. Y. , and Current Protocols in Molecular Biology (1996) John Wiley and Sons, Inc. , N. Y. ) which is incorporated herein by reference) which are provided throughout this document. All the information contained therein is incorporated herein by reference. Oligonucleotides can be synthesized on an Applied BioSystems oligonucleotide synthesizer [for details see Sinha et al. , Nucleic Acids Res. 12:4539 (1984)], according to specifications provided by the manufacturer. Complementary oligonucleotides are annealed by heating them to 90. degree. C. in a solution of 10 mM Tris-HCl buffer (pH 8. 0) containing NaCl (200 mM) and then allowing them to cool slowly to room temperature. For binding and turnover assays, duplex DNA is purified from native polyacrylamide (15% w/v) gels. The band corresponding to double-stranded DNA is excised and soaked overnight in 0. 30 M sodium acetate buffer (pH 5. 0) containing EDTA (1 mM). After soaking, the supernatant is extracted with phenol/chloroform (1/1 v/v) and precipitated with ethanol. DNA substrates are radiolabeled on their 5'-OH group by treatment with [g-. sup. 32P]ATP and T4 polynucleotide kinase. Salts and unincorporated nucleotides are removed by chromatography on Sephadex G columns
|
| Related patents |
|
|
Biodegradable and biocompatible polymeric microspheres encapsulating Salmonella enteritidis bacteria
In accordance with the present invention, there are provided long term release, biocompatible and biodegradable, porous, polymeric microcapsules comprising whole killed S...
|
|
|
Method for producing yeast expressed HPV types 6 and 16 capsid proteins
What is claimed is: 1. A virus-like particle (VLP) comprising a first late 1 (L1) capsid protein from human papilloma virus (HPV) type 6 and a second L1 capsid protein ...
|
|
|
Exchangeable template reaction
OF THE INVENTION Description of the Exchangeable Template Reaction (ETR) mechanism. The ETR is a method for the synthesis of long polynucleotide DNA fragments using ...
|
|
|
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
As has been discussed supra, it is desirable to produce human immunoglobulins that are reactive with specific human antigens that are promising therapeutic and/or ...
|
|
|
Transgenic non-human animals capable of producing heterologous antibodies
The design of a transgenic non-human animal that responds to foreign antigen stimulation with a heterologous antibody repertoire, requires that the heterologous ...
|
|
|
Transgenic non-human animals capable of producing heterologous antibodies
As has been discussed supra, it is desirable to produce human immunoglobulins that are reactive with specific human antigens that are promising therapeutic and/or ...
|
|
|
Transgenic non-human animals for producing heterologous antibodies
As has been discussed supra, it is desirable to produce human immunoglobulins that are reactive with specific human antigens that are promising therapeutic and/or ...
|
|
|
Nucleic acids encoding lymphoid CD30 antigen
We claim: 1. An isolated nucleic acid molecule comprising a polynucleotide having a sequence encoding the amino acid sequence of SEQ. ID. NO.: 2. 2. A recombinant vector ...
|
|
|
Feeding tray for multiwell test apparatus
This invention will be described herein with reference to the growing and use of cells on a membrane positioned and secured to the bottom of each of a multiplicity of ...
|
|
|
Neo-tryptophan
What is claimed is: 1. A method of making a neurotensin polypeptide containing neo-tryptophan, said method comprising: a) providing a neo-tryptophan derivative, and b) ...
|
|
|